Revelation Biosciences (FRA:56U0) Scaled Net Operating Assets : -0.42 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Revelation Biosciences's operating assets for the quarter that ended in Mar. 2024 was €0.14 Mil. Revelation Biosciences's operating liabilities for the quarter that ended in Mar. 2024 was €4.81 Mil. Revelation Biosciences's Total Assets for the quarter that ended in Dec. 2023 was €11.20 Mil. Therefore, Revelation Biosciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.42.

Revelation Biosciences Scaled Net Operating Assets Historical Data

The historical data trend for Revelation Biosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Scaled Net Operating Assets Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-0.23

-0.32

-2.20

-0.94

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial								-1.38	-0.23	-0.33	-0.37	-0.42

Competitive Comparison of Revelation Biosciences's Scaled Net Operating Assets

For the Biotechnology subindustry, Revelation Biosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Scaled Net Operating Assets falls into.

Revelation Biosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Revelation Biosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(0.202	-	5.103)	/	5.195
=	-0.94

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	11.199	-	10.997
=	0.202

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5.103	-	0	-	0
=	5.103

Revelation Biosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(0.138	-	4.81)	/	11.199
=	-0.42

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	13.526	-	13.388
=	0.138

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	4.81	-	0	-	0
=	4.81

Revelation Biosciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines